See today's BioWorld Science
To read the full story, subscribe or sign in.
Cancer

Nuvectis Pharma's NXP-800 granted orphan drug designation for cholangiocarcinoma

Aug. 18, 2023
The FDA has granted orphan drug designation to Nuvectis Pharma Inc.'s NXP-800 for the treatment of cholangiocarcinoma.
BioWorld Science Regulatory Cancer FDA Orphan drug